Articles by Keyword for

Both Germany and France have taken Actos off the market because of an increased risk of getting bladder cancer. The US is taking no action. Global sales of Actos are in the vicinity of $5 billion annually. All three "glitazone" drugs for type 2 diabetes have a poor track record. Rezulin was taken off the market more than a decade ago because it caused...

  Drugs that increase the sensitivity of insulin in theory should be effective in preventing and treating type 2 diabetes. However, the glitazone drugs have turned out to have serious side effects that limit their use in clinical practice. The drug, Actos, is the one glitazone that could possibly be safe and effective in both the prevention and treatment...

  The European "FDA" or European Medicines Agency (EMA) is in the process of opening its drug industry's research to independent researchers  so they can test company claims and expose product deficiencies. This will bring long sought after transparency to Big Pharma's research and claims made on their behalf. Both the FDA and...

  Even though Avandia increases both heart attacks and heart deaths the FDA has been lax in dealing with this problem. The incestuous relationship between the FDA and Big Pharma is disclosed.

Patients with COPD who use inhaled corticosteroids to improve breathing for more than 6 months have a 27% increased risk for bone fractures. The risk goes up as the dosage increases. It was previously assumed that inhaled steroids would have a predominantly local effect, but now we know this is not true. Treatment should consist of lowering or discontinuing inhaled...

Avandia remains on the market in the US despite serious health issues that include more than a 50% increase in heart attacks and mortality. All three "glitazones" have safety issues. Rezulin was taken off the market more than a decade ago because of severe liver disease. The third drug, Actos, remains suspicious but up to this point seems to be somewhat...

For patients over the age of 60 it appears that the target hemoglobin A1c level of less than 6.0% are associated with a higher death rate. This happens despite the fact that the complications of type 2 diabetes are far lower when A1c levels are less than 6.0%. The best overall outcomes occur with A1c levels between 6.0 and 8.0. Nonetheless, the best treatment...

  The Journal of the National Cancer Institute in August published an article showing that both Avandia and Actos increase bladder cancer by more than 400% compared to baseline incidence in diabetics. These drugs account for more than 20% of all drugs used to treat type 2 diabetes. Actos ranks 9th in the sales of all pharmaceutical drugs. This is remarkable...